Ying Zhu

Ying Zhu has held various roles in the pharmaceutical industry since 2003. Ying began their career at PDL BioPharma as a Staff Scientist. In 2009, they moved to Facet Biotech (a spin-off of PDL Biopharma) as a Senior Engineer II. In 2011, Ying Zhu joined Abbott Biotherapeutics Corp (Abbott's Acquisition of Facet Biotech) as a Senior Scientist III. Ying then moved to Boehringer Ingelheim in 2012 as an Associate Director of Cell Culture. In 2015, Ying Zhu joined Ankasa Regenerative Therapeutics as an Executive Director of Technical Operations. Most recently, in 2021, they became Vice President of CMC Development at Immune-Onc Therapeutics.

Ying Zhu obtained a PhD in Chemical Engineering from The Ohio State University between 1998 and 2002.